Rudin et al. Report extended follow-up of tarlatamab in SCLC
The authors reported that median overall survival was 13.6 months with tarlatamab versus 8.4 months with chemotherapy, with 12-month OS rates of 55.9% versus 39.0%. Grade ≥3 treatment-related adverse events decreased over time, with no serious events after 12 months.
Primary source
PubMed record of a Phase III journal article, October 26, 2026
Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study.
Read the source: Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study. pubmed.ncbi.nlm.nih.gov
Machine-summarized from the source above; not independently reported. How we use automation